Carboplatin (C) and docetaxel (D) in the second-line treatment of non-small cell lung cancer (NSCLC) patients pretreated with platinum-based regimens. A Phase II trial

被引:0
|
作者
Numico, G
Buffoni, L
Dongiovanni, V
Schena, M
Fissore, C
Fea, E
Occelli, M
Colantonio, I
Merlano, M
Bertetto, O
机构
[1] S Croce Gen Hosp, Cuneo, Italy
[2] S Giovanni Hosp, Turin, Italy
关键词
D O I
10.1016/S0169-5002(05)81035-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S260 / S260
页数:1
相关论文
共 50 条
  • [21] Phase I/II trial of docetaxel (D) and Carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Giannakakis, T
    Papadouris, S
    Kourousis, C
    Kalbakis, NK
    Tzianni, V
    Lidaki, E
    Androulakis, N
    Souklakos, J
    Sarra, E
    Georgoulias, V
    ANNALS OF ONCOLOGY, 1998, 9 : 94 - 94
  • [22] Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
    Leu, KM
    Kim, KM
    Larson, M
    Larson, M
    Schiller, JH
    LUNG CANCER, 2001, 34 (01) : 105 - 113
  • [23] Multicenter phase II trial of motexafin gadolinium (MGd) and pemetrexed (PEM) for second-line treatment in patients with non-small cell lung cancer (NSCLC)
    Edelman, Martin J.
    Otterson, Gregory A.
    Leach, Joseph
    Malpass, Thomas
    Salgia, Ravi
    Jones, Dennie
    Szakacs, Nancy
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S455 - S455
  • [24] Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study
    Agelaki, S
    Bania, H
    Kouroussis, C
    Blazoyiannakis, G
    Souglakos, J
    Tsiafaki, X
    Kalbakis, K
    Rapti, A
    Androulakis, N
    Georgoulias, V
    Papadakis, E
    LUNG CANCER, 2001, 34 : S77 - S80
  • [25] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [26] Sequential carboplatin-gemcitabine (CG) and docetaxel (D) in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): A phase II trial.
    Murad, AM
    Guimaraes, RC
    Scalabrini-Neto, AO
    Papa, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 708S - 708S
  • [27] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [28] Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer
    Choong, Nicholas W.
    Mazcer, Ann M.
    Hoffman, Philip C.
    Rudin, Charles M.
    Winegarden, Jerome D., III
    Villano, J. Lee
    Kozloff, Mark
    Wade, James L., III
    Sciortino, David F.
    Szeto, Livia
    Vokes, Everett E.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 245 - 251
  • [29] Phase II trial of temozolomide and irinotecan as second-line treatment for advance non-small cell lung cancer
    Choong, N
    Mauer, A
    Hoffman, P
    Ma, PR
    Cohen, E
    Rudin, C
    Kozloff, M
    Sciortino, D
    Szeto, L
    Vokes, E
    LUNG CANCER, 2005, 49 : S241 - S241
  • [30] Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
    Leighl, N
    Laurie, S
    Knox, J
    Ellis, P
    Shepherd, F
    Burkes, R
    Pond, G
    Zwiebel, J
    Moore, M
    LUNG CANCER, 2005, 49 : S256 - S256